RELIVE pivotal study final results show that Median’s eyonis™ LCS SaMD met all key endpoints, demonstrating statistically significant performance, superior to state of the art, as well as device safety and efficacy. The results support the intended use for which eyonis™ LCS was developed, which was shared with the EU Notified Body and discussed with the FDA during the Q-submission phase.

Median will be exhibiting at the ESMO Congress on October 17 – 21 in Berlin. Happy to see you there at Messe Berlin!

Median will be exhibiting at the 2025 ASCO Annual Meeting, which will take place from May 30 to June 3 in Chicago, IL.  Meet us  at McCormick Place South, Hall A, Booth #11046 to learn more about our breakthrough imaging solutions and services for oncology clinical trials.

eyonis™ Lung Cancer Screening (LCS) meets primary endpoint in RELIVE clinical trial, the final pivotal study required for regulatory submissions

Median Technologies releases today its 2024 key financial indicators (unaudited), and provides an outlook on the Company’s critical milestones in 2025.

Repayment of 2020 EIB loan to be rescheduled to October 2025 from April, new €37.5 million 2025 EIB loan under appraisal, final authorization stage and new up to €10 million equity line completed with IRIS to enable 2025 EIB loan